Ironwood Hits Phase III Endpoint In SBS-IF, But Shareholders Show Wariness

Looking to compete with Takeda’s Gattex in short bowel syndrome with intestinal failure, Ironwood succeeds in a Phase III trial, but investors may be concerned with misses on secondary endpoints.